WESTBURY, NY - Nov 27, 2017 - BioIVT, a leading provider of biospecimens and related services, today announced that it is launching a new line of products and services to improve safety, efficacy and toxicity testing for skin care products, cosmetics and topical medications.
As the demand for personal skin care products increases - whether they are applied for anti-aging, hydration, wound healing or UV protection purposes - so does the need for better safety, efficacy and toxicity testing systems. The same holds true for new cosmetics and topical medications, said Dr. Christopher Black, senior vice president of ADME-Tox at BioIVT. At BioIVT, we are endeavoring to provide researchers in those fields with biological systems that allow them to more clearly understand the disposition of topical applications and their effects on normal and disease-affected skin.
BioIVT now provides a wide range of skin products for safety, efficacy and toxicity testing. They include control tissue; disease-state skin punches for acne, atopic dermatitis, eczema, psoriasis and vitiligo; primary cell lines, such adipocytes, fibroblasts, keratinocytes, and melanocytes; and subcellular solutions. It also provides custom processing of skin samples and DNA/RNA extraction.
In addition, the company offers cell-based assay services. BioIVT works with a range of primary and immortalized skin cell lines and is able to produce high quality, phenotypically-relevant data. Its assays assess a variety of cell responses including cell toxicity, mitochondrial dysfunction, cell proliferation (ATP/MTT), oxidative stress and DNA damage.
BioIVT will be showcasing its new skin products and services at the DMDG Skin Metabolism Meeting, which will be held from Nov. 27-29 at the University of Sunderland in Sunderland, UK. The DMDG is a global association for scientists involved in drug metabolism and pharmacokinetic research and development.
Further information about this conference is available at
BioIVT, formerly known as BioreclamationIVT, is a worldwide provider of biological products to the life sciences and pharmaceutical industries. The company specializes in control and disease-state matrices manufactured from human and animal biological specimens and has recently expanded its offering to include cell processing, target and biomarker validation, ADMET, phenotypic assays to characterize novel therapeutics and the development of clinical assays. As a premier supplier of ADME-toxicology model systems, BioIVT enables scientists and biomedical researchers to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. BioIVTs reputation for providing exceptional customer service coupled with the highest quality biospecimens and services have made it the first-choice supplier for more than 35 years. For more information, please visit
or follow the company on Twitter @BiorecIVT.